Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
conteltinib
- Development stage
- Phase 2
- Lead developer
- Shouyao Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Conteltinib is a potent oral multi-kinase inhibitor primarily targeting anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK), and proline-rich tyrosine kinase 2 (Pyk2). It exhibits significant inhibitory activity against FAK with an IC50 of 1.6 nM. Conteltinib has demonstrated anti-tumor activity in preclinical and clinical studies, particularly in advanced ALK-positive non-small cell lung cancer (NSCLC) and pancreatic cancer. The drug also acts as an IGF type 1 receptor antagonist. Developed as a new molecular entity by Centaurus Biopharma and partners, it is currently in phase III clinical trials for NSCLC and pancreatic cancer[1][2][3][6][8].
- Brand names
- conteltinib
- Other names
- conteltinibCT 707CT707CT-707SY 707SY707SY-707
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)FAK (Focal adhesion kinase)IGF-1R (Insulin-like growth factor 1 receptor)PTK2B
Beyond the preview
Go deeper on conteltinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on conteltinib.